Optic Nerve and Retinal Imaging Methods (CPB 0344, reviewed 2026-05-26)
Summary
Aetna's Clinical Policy Bulletin 0344 covers optic nerve and retinal imaging. Aetna considers these imaging methods medically necessary for documenting the appearance of the optic nerve head and retina in conditions including age-related macular degeneration, diabetic retinopathy, glaucoma and glaucoma suspects, macular edema, macular hole, and screening and monitoring for toxicity from chloroquine, ethambutol, hydroxychloroquine, siponimod, vigabatrin and other listed drugs. Aetna considers OCT angiography (OCTA) medically necessary as an alternative to intravenous fluorescein angiography for listed retinal conditions, but considers performing both OCTA and fluorescein angiography, or both OCT and OCTA, for the same indication not medically necessary. Aetna considers these imaging methods experimental, investigational or unproven for uses such as cataracts, dry eye disease, routine screening of asymptomatic persons for glaucoma, and OCTA for diagnosing and monitoring glaucoma.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.